Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: February 24, 2007
Last updated: March 17, 2014
Last verified: March 2014
This is a double-blind, randomized, cross-over study conducted at centers within the United States. The study consists of five periods: an up to two-week Screening Period, a 5-week Run-In Period, two eight-week study treatment periods and a two-week Washout Period. Patients are assigned randomly (1:1) to one of two treatment sequences: sevelamer carbonate for eight weeks followed by sevelamer hydrochloride for eight weeks or sevelamer hydrochloride for eight weeks followed by sevelamer carbonate for eight weeks

Condition Intervention Phase
Chronic Kidney Disease
Drug: sevelamer carbonate, sevelamer hydrochloride
Drug: sevelamer hydrochloride, sevelamer carbonate
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Cross-Over Design Study of Sevelamer Hydrochloride (Renagel®) and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Safety-evaluated on the basis of adverse events (reported and/or observed) [ Time Frame: 16 weeks ]
  • changes in laboratory parameters, vital signs [ Time Frame: 16 weeks ]
  • note: clinically significant changes in physical examination were recorded and evaluated as adverse events [ Time Frame: 16 weeks ]
  • Efficacy-treatment regimens are compared on the basis of serum phosphorus at the end of each treatment period using the time-weighted mean of the phosphorus value from the last three visits in each treatment period [ Time Frame: 16 weeks ]
  • Treatment regimens were also compared with respect to total, LDL, and HDL cholesterol, and triglycerides, using the mean of values for each parameter from the two post-baseline assessments in each treatment period. [ Time Frame: 16 weeks ]

Enrollment: 80
Study Start Date: March 2005
Study Completion Date: July 2006
Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
sevelamer carbonate w(1-8) sevelamer hydrochloride w(9-16)
Drug: sevelamer carbonate, sevelamer hydrochloride
Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
sevelamer hydrochloride w(1-8) sevelamer carbonate w(9-16)
Drug: sevelamer hydrochloride, sevelamer carbonate
Starting dose individualized for each patient and fixed daily dose throughout both treatment periods

Detailed Description:
The study was conducted at 15 centers (2 of which did not enroll any patients). A total of 79 hemodialysis patients were assigned randomly to one of two treatment sequences.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patient had received hemodialysis three times per week for 3 months or longer;
  • patients were maintained on sevelamer hydrochloride as their primary phosphate binder with a total daily dose of ≤ 13.6 g with serum phosphorus concentrations at the last two measurements between 3.0 and 6.5 mg/dL, the most recent iPTH ≤ 600 pg/mL and the most recent serum calcium within the normal range.

Exclusion Criteria:

  • if patient had active bowel obstruction, dysphagia, swallowing disorders, or severe gastrointestinal motility disorders;
  • active ethanol or drug abuse (excluding tobacco);
  • need for antidysrhythmic or antiseizure medications used to control these conditions;
  • poorly controlled diabetes mellitus or hypertension;
  • active vasculitis;
  • active malignancy other than basal-cell carcinoma;
  • HIV infection; or
  • any clinically significant unstable medical condition as judge by the Investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00440648

United States, Alabama
Mobile, Alabama, United States, 36608
United States, California
Riverside, California, United States, 92501
United States, Colorado
Greenwood Village, Colorado, United States, 80111
United States, Illinois
Berwyn, Illinois, United States, 60402
Crestwood, Illinois, United States, 60445
United States, Indiana
Indianapolis, Indiana, United States, 46202
Valparaiso, Indiana, United States, 46383
United States, Missouri
Columbus, Missouri, United States, 39705
St. Louis, Missouri, United States, 63103
St. Louis, Missouri, United States, 63110
United States, North Carolina
Winston-Salem, North Carolina, United States, 27157
United States, Pennsylvania
Easton, Pennsylvania, United States, 19045
Wynnewood, Pennsylvania, United States, 19096
United States, Tennessee
Nashville, Tennessee, United States, 37205
United States, Virginia
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Genzyme, a Sanofi Company
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

Responsible Party: Medical Monitor, Genzyme Corporation Identifier: NCT00440648     History of Changes
Other Study ID Numbers: GD3-163-201
Study First Received: February 24, 2007
Last Updated: March 17, 2014

Additional relevant MeSH terms:
Renal Insufficiency, Chronic
Kidney Diseases
Renal Insufficiency
Urologic Diseases
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 26, 2017